title: Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab.
abstract: Dermatomyositis (DM) is a systemic autoimmune disorder characterized by the inflammation of skeletal muscles and pathognomonic skin rashes, namely heliotrope rash and Gottron's papules and involvement of other organs. Interstitial lung disease (ILD) seems to be one of the most characteristic manifestations of the lung and associated with increased morbidity and mortality in patients with DM. Despite DM-associated ILD requires aggressive therapy with cytotoxic agents, the efficacy is questionable in some cases, and more effective and less toxic therapies are needed. Recently, although there have been several reports of successful treatment of refractory case of PM and DM with the TNF-α antagonists, including infliximab and etanercept, there was no enough evidence for DM-associated ILD. We described herein a patient with DM-associated ILD who had poor response to conventional therapies and successfully treated with adalimumab.
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, San 2-20 Geumam-dong, Deokjin-gu, Jeonju, Jeonbuk 561-180, South Korea.
authors.forename: Jin-Kyoung
authors.initials: JK
authors.lastname: Park
authors.forename: Han-Gyul
authors.initials: HG
authors.lastname: Yoo
authors.forename: Dae-Seon
authors.initials: DS
authors.lastname: Ahn
authors.forename: Hyun-Soon
authors.initials: HS
authors.lastname: Jeon
authors.forename: Wan-Hee
authors.initials: WH
authors.lastname: Yoo
mesh_terms: D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003882:Dermatomyositis / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000188:drug therapy* / Q000209:etiology; D008875:Middle Aged; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab
references.citation: Arthritis Rheum. 2002 Dec 15;47(6):614-22
references.pmid: 12522835
references.citation: Clin Rheumatol. 2007 Jul;26(7):1186-8
references.pmid: 16736125
references.citation: Rheumatology (Oxford). 2005 Apr;44(4):562-3
references.pmid: 15695299
references.citation: Endocr Metab Immune Disord Drug Targets. 2006 Dec;6(4):409-15
references.pmid: 17214587
references.citation: J Invest Dermatol. 2002 Sep;119(3):617-20
references.pmid: 12230503
references.citation: Acta Neuropathol. 2000 May;99(5):585-8
references.pmid: 10805105
references.citation: Arthritis Rheum. 1994 Dec;37(12):1744-51
references.pmid: 7986220
references.citation: N Engl J Med. 1991 Nov 21;325(21):1487-98
references.pmid: 1658649
references.citation: Arthritis Rheum. 2005 Feb;52(2):601-7
references.pmid: 15692974
references.citation: Rheum Dis Clin North Am. 2002 Nov;28(4):799-822
references.pmid: 12506773
references.citation: Rheumatology (Oxford). 2004 Apr;43(4):531-2
references.pmid: 15024143
references.citation: Rheumatology (Oxford). 2004 Apr;43(4):524-6
references.pmid: 15024139
references.citation: Arthritis Care Res (Hoboken). 2010 Oct;62(10):1496-501
references.pmid: 20506189
references.citation: Clin Rheumatol. 2000;19(5):352-9
references.pmid: 11055823
references.citation: Rheumatology (Oxford). 2004 Sep;43(9):1198-9
references.pmid: 15317962